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Background    The Guideline Working Group of the Korean Society for Neuro-Oncology (KSNO) 
conducted a nationwide questionnaire survey for diverse queries faced in the treatment of brain tu-
mors. As part II of the survey, the aim of this study is to evaluate the national patterns of clinical prac-
tice for patients with diffuse midline glioma and meningioma.
Methods    A web-based survey was sent to all members of the KSNO by email. The survey in-
cluded 4 questions of diffuse midline glioma and 6 questions of meningioma (including 2 case scenari-
os). All questions were developed by consensus of the Guideline Working Group.
Results    In the survey about diffuse midline glioma, 76% respondents performed histologic 
confirmation to identify H3K27M mutation on immunohistochemical staining or sequencing methods. 
For treatment of diffuse midline glioma, respondents preferred concurrent chemoradiotherapy with 
temozolomide (TMZ) and adjuvant TMZ (63.8%) than radiotherapy alone (34.0%). In the survey 
about meningioma, respondents prefer wait-and-see policy for the asymptomatic small meningioma 
without peritumoral edema. However, a greater number of respondents had chosen surgical resec-
tion as the first choice for all large size meningiomas without exception, and small size meningiomas 
with either peritumoral edema or eloquent location. There was no single opinion with major consen-
sus on long-term follow-up plans for asymptomatic meningioma with observation policy. As many as 
68.1% of respondents answered that they would not add any adjuvant therapies for World Health Or-
ganization grade II meningiomas if the tumor was totally resected including dura.
Conclusion    The survey demonstrates the prevailing clinical practice patterns for patients with dif-
fuse midline glioma and meningioma among members of the KSNO. This information provides a point 
of reference for establishing a practical guideline in the management of diffuse midline glioma and 
meningioma.
Key Words  Korean Society for Neuro-Oncology; Practice patterns; Brain tumors; 
Diffuse midline glioma; Meningioma, Guideline Working Group.
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INTRODUCTION
The Guideline Working Group of Korean Society for Neu-
ro-Oncology (KSNO) conducted a nationwide questionnaire 
survey on the clinical practice about several topics of brain 
tumor. The intent of this survey study is described in the pre-
vious article of the series in this issue. As part II of the survey, 
this study deals with practical decisions of specific brain tu-
mors, such as diffuse midline glioma and meningioma.
Diffuse midline glioma is known to be one of dismal high-
grade pediatric and adult brain tumors involving midline struc-
tures of the central nervous system. In general, most of these 
tumors are inoperable because of challenging anatomic loca-
tion, which makes the prognosis even worse to the overall sur-
vival no more than 12 months [1-3]. There were few random-
ized controlled clinical trials to establish the evidence-based 
standard treatment protocol. Despite several therapeutic op-
tions including radiotherapy, chemotherapy and/or surgery, 
no superior treatment modalities could be recommended 
alone or in combination [4-6]. In addition, 2016 revised 
World Health Organization (WHO) classification recently re-
defined this type of tumors as diffuse midline glioma, H3K27M 
mutant, a new diagnostic entity based on its unique genetic sig-
nature [7]. So, evidence-based and consensus guideline from 
diagnosis to treatment for this entity is required.
Meningiomas are the most common primary brain tumors. 
The data from Korean Cancer Registration Statistics Program 
in 2013 shows that the incidence of meningioma was 37.3% of 
newly diagnosed brain tumors with median age at diagnosis 
of 61 years in Korea [8]. Recently, the incidence of meningio-
ma is continuously increasing due to the discovery of inciden-
tal meningiomas from expanded inclusion of neuroimaging in 
routine health check-ups [9-11]. However, the management 
strategy for incidental meningiomas is controversial among 
neurosurgeons [12-16]. Meningiomas were histologically clas-
sified into three grades by WHO definition from grade I to III. 
The definition of atypical meningioma (WHO grade II) from 
2016 revised WHO classification includes histologically con-
firmed brain invasion [7]. Contrast to grade I and grade III 
meningiomas, the adjuvant treatment after surgical resection 
for grade II meningiomas remains debating issue among phy-
sicians. Some studies reported that adjuvant radiotherapy after 
neurosurgical resection decreased the recurrence rates and im-
proved overall survival [17,18]. However, there are also other 
studies describing no benefit in recurrence and survival of ad-
juvant radiotherapy at the cost of its risk of radiation-induced 
toxicity [19,20]. 
The aim of this study is to evaluate the tendencies of clinical 
practice for patients with diffuse midline glioma and menin-
gioma from the nationwide survey in Korea.
MATERIALS AND METHODS
The details of the study design, outline, and implementation 
are described in the previous article of the series in this issue. 
Here, the questionnaires about diffuse midline glioma (4 ques-
tions) and meningioma (6 questions) were structured around 
existing controversies regarding real clinical management in 
patients (Appendix). 
Regarding the diffuse midline glioma, the questionnaires 
were focused on the diagnosis and treatment options in clini-
cal practices. The dose and target of radiotherapy that consid-
ered as the significant treatment option were also investigated. 
The questionnaires of meningioma included 2 case scenari-
os asking the management options for the patients with as-
ymptomatic meningioma with different age and radiological 
finding of the tumor. Other questionnaire consisted of follow-
up MRI schedules for asymptomatic meningioma, adjuvant 
treatment of WHO grade II meningioma according to the ex-
tent of surgical resection, adjuvant radiation dose of WHO 
grade II meningioma after surgical resection, and experience 
of medical treatment for patients with meningioma.
RESULTS
Diffuse midline glioma
About three quarters of the respondents performed the di-
agnostic confirmation to identify the H3K27M mutation (n= 
36, 72%) by the immunohistochemical (IHC) staining or the 
pathognomonic K27M mutation (n=20, 40%) in the histone 
3.3 (H3.3) gene H3F3A, histone 3.2 (H3.2) gene HIST2H3C, 
and histone 3.1 (H3.1) genes HIST1H3B/C using sequencing 
methods. Twelve respondents (24%) diagnosed the diffuse 
midline glioma by using only radiologic findings without de-
tection of H3K27M mutation.
For treatment of diffuse midline glioma, 30 of 47 (63.8%) re-
spondents performed the concurrent chemoradiotherapy with 
temozolomide (TMZ) and adjuvant TMZ, and 16 respondents 
(34.0%) treated the patient with radiotherapy alone. One re-
spondent reported that if surgically total resection was per-
formed, no further treatment was given. For radiation dose, 
42 of 45 (93.4%) respondents mostly delivered 54–60 Gy in 
27–30 fractions. Two (4.4%) respondents delivered 45 Gy in 
25 fractions, and one (2.2%) respondent stated in free text re-
sponse that the radiation dose was decided according to loca-
tion of lesions (i.e., 54 Gy in 30 fractions for brainstem lesion 
and 60 Gy in 30 fractions for the others). The target coverage 
of radiotherapy showed that mainly focused on the high signal 
intensity lesion of T2-weighted MRI (Fig. 1).
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tion with serial MRI follow-up, but for patients with peritu-
moral edema, surgical resection was preferred. For patients 
with parasagittal meningioma around the motor cortex, re-
spondents preferred the surgical resection regardless of peri-
tumoral edema. If the tumor was located at skull base, the deci-
sion was quite similar to that of frontal convexity tumor, but the 
role of radiosurgery was emphasized all the more. However, 
the majority of respondents opted for surgical resection for a 
70-year-old woman with meningioma with larger tumor (6 
cm in diameter) regardless of tumor location and peritumoral 
edema (Fig. 2). The responses of case scenarios showed that 
the radiologic findings, such as tumor location, tumor size, and 
peritumoral edema, were considered more important factors 
than age of patient in determining treatment strategies of as-
ymptomatic meningioma.
Fig. 3 shows responses about radiological follow-up plans 
for patients with asymptomatic meningioma by each respon-
dent. Among 45 respondents who answered to have follow-
up plans, 12 respondents (26.7%) had no long-term plans for 
radiological follow-up after a year if the tumor is stable. We 
could find that every respondent has different ideas on follow-
up plans for the meningiomas with observation policy. There 
was no single opinion with major consensus on long-term fol-
low-up plans. 
Among 47 respondents, 32 (68.1%) respondents choose 
observation with serial MRI follow-up without adjuvant treat-
ment for patient with WHO grade II meningioma receiving 
Meningioma
We asked the decision on initial management plan for inci-
dentally found asymptomatic meningiomas based on case 
scenarios. The preference of treatment modality for a 45-year-
old woman with small (3 cm in diameter) meningioma was 
quite variable according to tumor location and presence of per-
itumoral edema (Fig. 2). For frontal convexity meningioma 
without peritumoral edema, respondents preferred observa-
Fig. 1. Pie chart demonstrating target of radiotherapy. Note that 
over 65% of respondents mainly performed radiotherapy focused 
on the high signal intensity lesion of T2-weighted MRI.
Fig. 2. Treatment modality preference of respondents for a 45-year-old woman with 3-cm-sized asymptomatic meningioma (left), and 70-year-
old woman with 6-cm-sized asymptomatic meningioma (right) according to tumor location and presence of peritumoral edema (PTE).
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complete tumor resection with removal of affected dura, 
while 14 (29.8%) respondents performed the radiotherapy 
and one (2.1%) respondent performed the radiosurgery. For 
patients with WHO grade II meningioma receiving complete 
tumor resection without removal of affected dura, 31 of 47 
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Fig. 3. Responses about radiological follow-up plans for patients with asymptomatic meningioma by each respondent. Colored cells are time 
points to study. Responses with blue cells are answers with any consensus for long-term follow-up plans, while those with grey cells are with 
no plan for long-term follow ups after a year. 
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(8.5%) respondents performed the radiosurgery. Twelve 
(25.5%) respondents choose observation without adjuvant 
treatment in this setting. For patient with WHO grade II me-
ningioma with residual tumor after surgery, respondents 
choose the next plan as following: radiotherapy (n=34, 72.4%), 
radiosurgery (n=12, 25.5%), and observation without adjuvant 
treatment (n=1, 2.1%). Regarding the radiation dose given after 
surgical resection, 28 of 42 (66.7%) respondents delivered 54.0 
Gy after surgical resection for WHO grade II meningioma. Ten 
(23.8%) respondents delivered 60.0 Gy and three (7.0%) deliv-
ered 58.8 Gy. In free text responses, one respondent stated that 
the radiation dose was decided according to whether perform-
ing complete tumor resection or not. Twelve respondents de-
scribed their experiences of a medical treatment trial for pa-
tients with meningioma. The prescribed medications were the 
following: hydroxyurea (n=11); nimustine plus cisplatin (n=1); 
nitrosourea (n=1).
DISCUSSION
The characteristic findings of diffuse midline glioma are 
known as K27M mutations in the histone H3 gene H3F3A, or 
less commonly in the related HIST1H3B gene, a diffuse growth 
pattern, and a midline location of brain (e.g., thalamus, brain 
stem, and spinal cord) [7,21,22]. Because surgical resection is 
often difficult due to the location of the tumor, proper imag-
ing and biopsy are required for accurate differential diagnosis. 
In this survey report, three-quarters of respondents consider 
that histologic confirmation of the H3K27M mutation is more 
important for diagnosis, based on the 2016 revised WHO clas-
sification [7]. This is in line with the diagnosis of diffuse mid-
line glioma in the European Assocation for Neuro-Oncology 
guideline that recommends IHC of histone H3K27M mutation 
which characterizes diffuse midline glioma, histone H3K27M-
mutant [23]. Therefore, if possible, the histologic confirmation 
of the H3K27M mutation would be considered as a diagnostic 
criterion.
Current treatment strategy for diffuse midline glioma is that 
conventional radiotherapy is the important therapeutic option 
due to the limitation of radical resection [23,24]. The role of 
chemotherapy remains unclear. Several types of chemothera-
peutic regimens such as carboplatin, etoposide, vincristine and 
TMZ have shown no evidence of survival improvement [25-
29]. Some physicians have used chemotherapy with or after 
radiotherapy following the standards of care for gliomas of the 
same WHO grade in other anatomical locations. EANO guide-
line recommends radiotherapy alone or TMZ plus radiother-
apy followed by TMZ as first line treatment [23]. Our results 
also seem to reflect this situation in the real world. The stan-
dard radiation dose is 54–60 Gy with a daily conventional frac-
tionation of 1.8–2.0 Gy [24]. Some studies for the altered frac-
tionation schemes including the hypofractionation with shorter 
treatment duration or hyperfractionation with dose-escalation 
have shown no distinct survival benefit [1-3,5,30,31]. To over-
come the limitation of few therapeutic options, there is a con-
tinuing need for new clinical trials to find a new therapeutic 
strategy and basic research to increase insight to diffuse mid-
line glioma.
This nationwide survey study reflects various opinions on 
the treatment of asymptomatic meningioma and postoperative 
treatment of WHO grade II meningioma. There have been 
many reports about the strategy for asymptomatic meningio-
mas. The prospective study dealing with the natural history of 
incidental meningioma reported that asymptomatic tumors 
can be safely managed by imaging follow-up, although 75% of 
meningioma had slowly increased on observation period. It 
was also reported that the growth rate was significantly corre-
lated with the tumor size and the age of patients [32]. Kim et 
al. [33] reported the comparison result of Gamma Knife sur-
gery (GKS) versus observation in 354 patients with asymp-
tomatic meningiomas. The clinical and radiologic progres-
sion-free survival rates at 10 years were 92.9% and 88.5% in 
GKS group, while those were 42.7% and 7.9% in observation 
group. Clinical progression was correlated with young age, 
absence of calcification, peritumoral edema, and high T2 sig-
nal intensity in the observation group [33]. In another report, 
603 patients with asymptomatic meningiomas were respec-
tively analyzed about the natural course and surgical outcome 
[16]. A total of 63% of asymptomatic meningiomas did not 
grow in follow up for longer than 5 years, and only 6% of all 
patients with these lesions showed symptoms during the ob-
servation period. Among the 213 patients underwent the neu-
rosurgical resection, the morbidity rate was 4.4% in patients 
younger than 70 years of age and 9.4% in those 70 years of age 
or older, and those were lower compared with those in symp-
tomatic patients [16]. Zeng et al. [34] reported that Simpson I 
resection rate was significantly high in the cerebral hemi-
spheric tumor compared with skull base lesion (95.2% vs. 
66.7%) in the patient with asymptomatic meningiomas. The 
surgical-related complication rate was 13.6%, which was lower 
than the rate of 21.7% in the symptomatic patients, and young-
er patients less than 60 years showed better outcome at 1 year 
after the operation. In the current survey, the respondents rath-
er choose an aggressive treatment of neurosurgical resection 
or radiosurgery except for the situations with middle-aged pa-
tients having 3-cm-sized frontal convexity without peritu-
moral edema. The size of tumors rather than age and the peri-
tumoral edema tended to be the determining factors whether to 
treat or not. Additionally, the neurosurgical resection was more 
preferred compared to radiosurgery as the treatment strategy 
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in patients with asymptomatic meningiomas.
There have been several controversies in management of 
WHO grade II meningiomas, including the significance of ex-
tent of surgical resection, the postoperative radiotherapy, and 
chemotherapy. In the conclusion of previous review on these 
issues in non-benign meningiomas, gross total resection 
could improve outcome and should be attempted in grade II 
meningiomas [35]. They also reported that postoperative ra-
diotherapy following gross total resection did not improve 
patient outcome of grade II meningioma, but radiotherapy 
improves outcome following subtotal tumor resection of 
grade II meningioma. Additionally, no drug therapy was not 
effective to improve outcome in non-benign meningiomas 
[35]. Sun et al. [36] reported the treatment algorithm based on 
the investigation of previous studies in WHO grade II menin-
giomas. They recommended that adjuvant radiotherapy could 
be considered when tumors showed high risk features, such as 
brain invasion, mitotic index ≥8, and sheeting, although gross 
total resection was performed. And stereotactic radiosurgery 
as well as radiotherapy could be suitable in the patients after 
subtotal resection [36]. In this study, there was the opposite 
opinion about the necessity of postoperative radiotherapy ac-
cording to the presence of affected dura even if gross total re-
section was performed. However, respondents concurred 
with the previous results about the management following 
subtotal resection.
As with any online survey, the major limitation of this study 
is response bias that respondents might be influenced by the 
pressure to follow the published guidelines, especially in the 
survey of diffuse midline glioma because of a rare disease en-
tity. Additionally, the relatively low response rate may give rise 
to sampling bias interfering with the valuable interpretation 
of several questions. 
In conclusion, the survey demonstrates the variation and 
similarity of clinical practice for patients with diffuse midline 
glioma and meningioma among members of the KSNO. It is 
important to reduce the variation for establishing the guideline 
based on the best available evidence. 
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Appendix
Diffuse midline glioma
1.  How is diffuse midline glioma diagnosed in your institution? (Choose all that apply) 
(      )  By using only radiologic finding 
(      )  By identifying the H3K27M mutation on the IHC staining 
(      )  By identifying the H3F3A, HIST1H3B, HIST1H3C mutation on the sequencing method
2.  How do you treat diffuse midline glioma after diagnosis? 
(      )  Radiotherapy only 
(      )  Concurrent chemoradiotherapy with TMZ and adjuvant TMZ (standard treatment protocol of glioblastoma)
3.  What is the dose fractionation schedule of radiotherapy for diffuse midline glioma in your institution? (Skip the question if you 
don’t perform the radiotherapy for diffuse midline glioma) 
(      )  45 Gy/25 fractions 
(      )  54 Gy/27 fractions 
(      )  60 Gy/30 fractions 
(      )  Other
4.  What is the target coverage of radiotherapy for diffuse midline glioma in your institution? (Skip the question if you don’t 
perform the radiotherapy for diffuse midline glioma) 
(      )  Enhancing area of T1-weighted MRI 
(      )  High signal intensity area of T2-weighted MRI 
(      )  All regions involving tumors 
(      )  Whole brain
Meningioma
1.  For a 45-year-old female with incidentally found meningioma of 3 cm in size, what treatment would you recommend for a 
patient according to tumor location and peritumoral edema (+presence, -absence)?
a)  Frontal convexity, peritumoral edema (-) 
(      )  Observation with serial MRI follow-up 
(      )  Surgical resection 
(      )  Radiosurgery
b)  Frontal convexity, peritumoral edema (+) 
(      )  Observation with serial MRI follow-up 
(      )  Surgical resection 
(      )  Radiosurgery
c)  Motor cortex/parasagittal, peritumoral edema (-) 
(      )  Observation with serial MRI follow-up 
(      )  Surgical resection 
(      )  Radiosurgery
d)  Motor cortex/parasagittal, peritumoral edema (+) 
(      )  Observation with serial MRI follow-up 
(      )  Surgical resection 
(      )  Radiosurgery
e)  Skull base, peritumoral edema (-) 
(      )  Observation with serial MRI follow-up 
(      )  Surgical resection 
(      )  Radiosurgery
f)  Skull base, peritumoral edema (+) 
(      )  Observation with serial MRI follow-up 
(      )  Surgical resection 
(      )  Radiosurgery
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2.  For a 70-year-old female with incidentally found meningioma of 6 cm in size, what treatment would you recommend for a 
patient according to tumor location and peritumoral edema (+presence, -absence)?
a)  Frontal convexity, peritumoral edema (-) 
(      )  Observation with serial MRI follow-up 
(      )  Surgical resection 
(      )  Radiosurgery
b)  Frontal convexity, peritumoral edema (+) 
(      )  Observation with serial MRI follow-up 
(      )  Surgical resection 
(      )  Radiosurgery
c)  Motor cortex/parasagittal, peritumoral edema (-) 
(      )  Observation with serial MRI follow-up 
(      )  Surgical resection 
(      )  Radiosurgery
d)  Motor cortex/parasagittal, peritumoral edema (+) 
(      )  Observation with serial MRI follow-up 
(      )  Surgical resection 
(      )  Radiosurgery
e)  Skull base, peritumoral edema (-) 
(      )  Observation with serial MRI follow-up 
(      )  Surgical resection 
(      )  Radiosurgery
f)  Skull base, peritumoral edema (+) 
(      )  Observation with serial MRI follow-up 
(      )  Surgical resection 
(      )  Radiosurgery
3.  What is your favorite follow-up MRI schedule of asymptomatic meningioma? (Choose all the time that you prefer to perform MRI) 
(      )  6 months,   (      )  1 year,   (      )  2 years,   (      )  3 years,   (      )  4 years,   (      )  5 years, 
(      )  6 years,   (      )  7 years,   (      )  8 years,   (      )  9 years,   (      )  10 years
4.  What adjuvant treatment would you recommend for patients with WHO grade II meningioma according to the extent of 
surgical resection?
a)  Complete tumor resection with removal of affected dura 
(      )  Close observation with serial MRI follow-up 
(      )  Radiosurgery 
(      )  Radiotherapy
b)  Complete tumor resection without removal of affected dura 
(      )  Close observation with serial MRI follow-up 
(      )  Radiosurgery 
(      )  Radiotherapy
c)  Presence of residual tumor 
(      )  Close observation with serial MRI follow-up 
(      )  Radiosurgery 
(      )  Radiotherapy
5.  What is the radiation dose of adjuvant radiotherapy after surgical resection for patients with WHO grade II meningioma in 
your institution? 
(      )  54 Gy      (      )  58.8 Gy      (      )  60 Gy      (      )  Other
6.  Have you ever tried chemotherapy for patients with WHO grade II meningioma? If you have, describe the regimen of  
chemotherapy. 
(      )  No 
(      )  Yes (                                                               )
